In a prospective analysis conducted on clinical trials including patients who were hospitalized with COVID-19, administration of IL-6 antagonists showed a reduction in 28-day all-cause mortality in comparison to traditional treatment or placebo (130). The gene discussed is IL6; the disease is COVID-19.